Document is current
Any future updates will be listed below
-
Authors
Dobrowolska Zakaria, Justyna A.
Bateman, Randall J.
Lysakowska, Monika
Khatri, Ammaarah
Jean-Gilles, Dinorah
Kennedy, Matthew E.
Vassar, Robert
-
Funding
Funding for this research was provided by:
Northwestern University Clinical and Translational Sciences Institute (Pilot Award UL1TR001422)
BrightFocus Foundation (A2019520S)
National Institute on Aging (T32 AG20506 (Mechanisms of Aging and Dementia Training Grant))
Anonymous Foundation
National Institutes of Health (R01NS065667)
- License Information
-
More Information
Article History
Received: 2 February 2022
Accepted: 22 August 2022
First Online: 2 September 2022
Competing interests
: The authors declare the following competing interests: J. A. Dobrowolska Zakaria has previously received royalty income based on technology (stable isotope labeling kinetics) licensed by Washington University to C2N Diagnostics. M. E. Kennedy and D. Jean-Gilles are employed by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and provided antibodies for this study. R. J. Bateman co-founded C2N Diagnostics. Washington University and R. J. Bateman have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (stable isotope labeling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics. He receives income from C2N Diagnostics for serving on the scientific advisory board. He consulted for Roche, Genentech, AbbVie, Pfizer, Boehringer-Ingelheim, and Merck. R. Vassar serves on the Scientific Advisory Board of Alector and owns Alector stock. Northwestern University and R. Vassar receive royalty income from licensing of the 5XFAD mouse. M. Lysakowska and A. Khatri declare no potential conflict of interest.
